Accepted at 2:04 a.m. Nov, 01, 2023 by GroupG_Strep93
Author: GroupG_Strep93
Related Note: 1481330704958
Rationale for change

only an oncogene once it's mutated; generally it's a proto-oncogene

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::#AMBOSS::Et0823 #AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step2_v12::#AMBOSS::tS0XYf #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#AMBOSS::V-0Gwi #AK_Step1_v12::#Pixorize::02_Immunology::07_Leukemias_&_Lymphomas::04_Chronic_Myelogenous_Leukemia_(CML) #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::32_Chromosomal_translocations::*22 #AK_Step1_v12::#USMLERx::43200.1 #AK_Step2_v12::#OME::01_Medicine::05_Hematology_Oncology::05_Leukemia #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::01_Acute_Leukemias_SOAP #AK_Step1_v12::#AMBOSS::IQaYx4 #AK_Step1_v12::#UWorld::COMLEX::25363 #AK_Step2_v12::#AMBOSS::Dt01f3 #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Step1_v12::#UWorld::Step::12278 #AK_Step1_v12::#B&B::12_Hematology::03_White_Blood_Cells::02_Chronic_Leukemia #AK_Step1_v12::#FirstAid::04_Pathology::03_Neoplasia::08_Oncogenes::*Signal_Transducers::BCR-ABL #AK_Step2_v12::#UWorld::Step::2894 #AK_Step1_v12::#B&B::09_Endocrinology::05_Other::06_Signaling_Pathways::Extra #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::03_Leukemia #AK_Step1_v12::#UWorld::COMLEX::25844 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::02_Chronic_Leukemias_SOAP #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::leukemia #AK_Step1_v12::#B&B::12_Hematology::03_White_Blood_Cells::01_Acute_Leukemia #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::09_Oncogenes_and_Tumor_Suppressor_Genes #AK_Step1_v12::#UWorld::Step::8281 #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::03_Leukemia #AK_Step1_v12::#Pathoma::06_WBC::04_Myeloproliferative #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::*Chronic_Myeloproliferative_Disorders::Chronic_Myelogenous_Leukemia #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::02_Acute_Myeloid_Leukemia_(AML)_&_Chronic_Myeloid_Leukemia_(CML) #AK_Step2_v12::#UWorld::COMLEX::28704 #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::09_Oncogenes_and_Tumor_Suppressor_Genes #AK_Step2_v12::#AMBOSS::xt0Ef3 #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::04_Chronic_Leukemias #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::09_Leukemias_and_Lymphomas::02_Chronic_Myeloid_Leukemia #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::01_Myeloproliferative_Disorders_Overview #AK_Step2_v12::#AMBOSS::o-a0yM #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders #AK_Step1_v12::#Physeo::11_Pathology::07_General_Pathology::09_Carcinogenesis #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::leukemia